RNXT

SEC source: 0001641172-25-003631 · ownership.xml · nonDerivative · entry 1

Agah Ramtin · CIK 0001862617 · Director · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,078,460

F1 · shares: Reflects open market purchases of the Issuer's securities.

F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price.

SEC source: 0001641172-25-003496 · ownership.xml · nonDerivative · entry 1

Marton Laurence · CIK 0001862192 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,684

F1 · shares: Reflects an open market purchase of the Issuer's securities.

SEC source: 0001641172-25-003364 · ownership.xml · nonDerivative · entry 1

Agah Ramtin · CIK 0001862617 · Director · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,048,460

F1 · shares: Reflects open market purchases of the Issuer's securities.

F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.825 to $0.8499, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.

F3 · balance_after: Includes 975,000 shares, which are held of record by the reporting person currently and were held of record by the Mars16 Nevada Non-Grantor Trust Dtd 01/19/2016 and reported as indirectly held by the reporting person previously.

F3 · ownership.direct: Includes 975,000 shares, which are held of record by the reporting person currently and were held of record by the Mars16 Nevada Non-Grantor Trust Dtd 01/19/2016 and reported as indirectly held by the reporting person previously.

SEC source: 0001641172-25-003675 · ownership.xml · nonDerivative · entry 1

Kocak Ron · CIK 0002011160 · VP Controller and PAO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 95

F1 · shares: Reflects open market purchases of the Issuer's securities.

SEC source: 0001641172-25-003158 · ownership.xml · nonDerivative · entry 1

Bagai Shaun · CIK 0001862613 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 302,540

F1 · shares: Reflects open market purchases of the Issuer's securities.

F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.816 to $0.85, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.

SEC source: 0001493152-24-039213 · ownership.xml · derivative · entry 1

Macfarlane K. Angela · CIK 0001865182 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,099

Underlying: Common Stock · 25,099 shares

Expires 2034-10-01

F1 · derivative.exercise_date: The shares subject to the option vest in 12 equal monthly installments beginning on November 1, 2024.

SEC source: 0001493152-24-039217 · ownership.xml · derivative · entry 1

Marton Laurence · CIK 0001862192 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,099

Underlying: Common Stock · 25,099 shares

Expires 2034-10-01

F1 · derivative.exercise_date: The shares subject to the option vest in 12 equal monthly installments beginning on November 1, 2024.

SEC source: 0001493152-24-039216 · ownership.xml · derivative · entry 1

Spiegel Robert J. · CIK 0001492256 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,099

Underlying: Common Stock · 25,099 shares

Expires 2034-10-01

F1 · derivative.exercise_date: The shares subject to the option vest in 12 equal monthly installments beginning on November 1, 2024.

SEC source: 0001493152-24-039214 · ownership.xml · derivative · entry 1

RYAN UNA S · CIK 0001255349 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,099

Underlying: Common Stock · 25,099 shares

Expires 2034-10-01

F1 · derivative.exercise_date: The shares subject to the option vest in 12 equal monthly installments beginning on November 1, 2024.

SEC source: 0001493152-24-009409 · ownership.xml · derivative · entry 1

Gentry Leesa · CIK 0002013097 · Chief Clinical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 190,000

Underlying: Common Stock · 190,000 shares

Expires not disclosed

F1 · price: Represents 10-year incentive stock options to purchase 190,000 shares of the Company's common stock pursuant to the Company's 2021 Omnibus Equity Incentive Plan. These options vest over four years at a rate of 1/48 per month, beginning to vest on March 1, 2024.

F1 · derivative.exercise_date: Represents 10-year incentive stock options to purchase 190,000 shares of the Company's common stock pursuant to the Company's 2021 Omnibus Equity Incentive Plan. These options vest over four years at a rate of 1/48 per month, beginning to vest on March 1, 2024.

F1 · derivative.expiration_date: Represents 10-year incentive stock options to purchase 190,000 shares of the Company's common stock pursuant to the Company's 2021 Omnibus Equity Incentive Plan. These options vest over four years at a rate of 1/48 per month, beginning to vest on March 1, 2024.

SEC source: 0001493152-24-005939 · ownership.xml · derivative · entry 1

Kocak Ron · CIK 0002011160 · VP, Controller and PAO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires not disclosed

F1 · price: Represents 10-year incentive stock options to purchase 15,000 shares of the Company's common stock pursuant to the Company's 2021 Omnibus Equity Incentive Plan. These options vest over four years at a rate of 1/48 per month, beginning vesting on the date.

F1 · derivative.exercise_date: Represents 10-year incentive stock options to purchase 15,000 shares of the Company's common stock pursuant to the Company's 2021 Omnibus Equity Incentive Plan. These options vest over four years at a rate of 1/48 per month, beginning vesting on the date.

F1 · derivative.expiration_date: Represents 10-year incentive stock options to purchase 15,000 shares of the Company's common stock pursuant to the Company's 2021 Omnibus Equity Incentive Plan. These options vest over four years at a rate of 1/48 per month, beginning vesting on the date.

SEC source: 0001493152-24-004364 · ownership.xml · derivative · entry 2

Macfarlane K. Angela · CIK 0001865182 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,983

Underlying: Common Stock · 40,983 shares

Expires not disclosed

F1 · price: Reporting Person purchased 40,983 shares of common stock and warrants to purchase 40,983 shares of common stock for a purchase price of $1.22 per share of common stock and associated warrant exercisable for one share of common stock in a private placement offering by the company made pursuant to Rule 506(c) of the Securities Act of 1933, as amended. The warrants are exercisable immediately, at an exercise price of $1.22 per share, subject to certain adjustments, and expire on January 30, 2029.

F1 · derivative.exercise_date: Reporting Person purchased 40,983 shares of common stock and warrants to purchase 40,983 shares of common stock for a purchase price of $1.22 per share of common stock and associated warrant exercisable for one share of common stock in a private placement offering by the company made pursuant to Rule 506(c) of the Securities Act of 1933, as amended. The warrants are exercisable immediately, at an exercise price of $1.22 per share, subject to certain adjustments, and expire on January 30, 2029.

F1 · derivative.expiration_date: Reporting Person purchased 40,983 shares of common stock and warrants to purchase 40,983 shares of common stock for a purchase price of $1.22 per share of common stock and associated warrant exercisable for one share of common stock in a private placement offering by the company made pursuant to Rule 506(c) of the Securities Act of 1933, as amended. The warrants are exercisable immediately, at an exercise price of $1.22 per share, subject to certain adjustments, and expire on January 30, 2029.

SEC source: 0001493152-24-004364 · ownership.xml · nonDerivative · entry 1

Macfarlane K. Angela · CIK 0001865182 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,983

F1 · price: Reporting Person purchased 40,983 shares of common stock and warrants to purchase 40,983 shares of common stock for a purchase price of $1.22 per share of common stock and associated warrant exercisable for one share of common stock in a private placement offering by the company made pursuant to Rule 506(c) of the Securities Act of 1933, as amended. The warrants are exercisable immediately, at an exercise price of $1.22 per share, subject to certain adjustments, and expire on January 30, 2029.

SEC source: 0001493152-24-004366 · ownership.xml · derivative · entry 2

Marton Laurence · CIK 0001862192 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,196

Underlying: Common Stock · 8,196 shares

Expires not disclosed

F1 · price: Reporting Person purchased 8,196 shares of common stock and warrants to purchase 8,196 shares of common stock for a purchase price of $1.22 per share of common stock and associated warrant exercisable for one share of common stock in a private placement offering by the company made pursuant to Rule 506(c) of the Securities Act of 1933, as amended. The warrants are exercisable immediately, at an exercise price of $1.22 per share, subject to certain adjustments, and expire on January 30, 2029.

F1 · derivative.exercise_date: Reporting Person purchased 8,196 shares of common stock and warrants to purchase 8,196 shares of common stock for a purchase price of $1.22 per share of common stock and associated warrant exercisable for one share of common stock in a private placement offering by the company made pursuant to Rule 506(c) of the Securities Act of 1933, as amended. The warrants are exercisable immediately, at an exercise price of $1.22 per share, subject to certain adjustments, and expire on January 30, 2029.

F1 · derivative.expiration_date: Reporting Person purchased 8,196 shares of common stock and warrants to purchase 8,196 shares of common stock for a purchase price of $1.22 per share of common stock and associated warrant exercisable for one share of common stock in a private placement offering by the company made pursuant to Rule 506(c) of the Securities Act of 1933, as amended. The warrants are exercisable immediately, at an exercise price of $1.22 per share, subject to certain adjustments, and expire on January 30, 2029.

SEC source: 0001493152-24-004366 · ownership.xml · nonDerivative · entry 1

Marton Laurence · CIK 0001862192 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,634

F1 · price: Reporting Person purchased 8,196 shares of common stock and warrants to purchase 8,196 shares of common stock for a purchase price of $1.22 per share of common stock and associated warrant exercisable for one share of common stock in a private placement offering by the company made pursuant to Rule 506(c) of the Securities Act of 1933, as amended. The warrants are exercisable immediately, at an exercise price of $1.22 per share, subject to certain adjustments, and expire on January 30, 2029.

SEC source: 0001493152-24-004368 · ownership.xml · derivative · entry 2

Bagai Shaun · CIK 0001862613 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,983

Underlying: Common Stock · 40,983 shares

Expires not disclosed

F1 · price: Reporting Person purchased 40,983 shares of common stock and warrants to purchase 40,983 shares of common stock for a purchase price of $1.22 per share of common stock and associated warrant exercisable for one share of common stock in a private placement offering by the company made pursuant to Rule 506(c) of the Securities Act of 1933, as amended. The warrants are exercisable immediately, at an exercise price of $1.22 per share, subject to certain adjustments, and expire on January 30, 2029.

F1 · derivative.exercise_date: Reporting Person purchased 40,983 shares of common stock and warrants to purchase 40,983 shares of common stock for a purchase price of $1.22 per share of common stock and associated warrant exercisable for one share of common stock in a private placement offering by the company made pursuant to Rule 506(c) of the Securities Act of 1933, as amended. The warrants are exercisable immediately, at an exercise price of $1.22 per share, subject to certain adjustments, and expire on January 30, 2029.

F1 · derivative.expiration_date: Reporting Person purchased 40,983 shares of common stock and warrants to purchase 40,983 shares of common stock for a purchase price of $1.22 per share of common stock and associated warrant exercisable for one share of common stock in a private placement offering by the company made pursuant to Rule 506(c) of the Securities Act of 1933, as amended. The warrants are exercisable immediately, at an exercise price of $1.22 per share, subject to certain adjustments, and expire on January 30, 2029.

SEC source: 0001493152-24-004368 · ownership.xml · nonDerivative · entry 1

Bagai Shaun · CIK 0001862613 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 292,540

F1 · price: Reporting Person purchased 40,983 shares of common stock and warrants to purchase 40,983 shares of common stock for a purchase price of $1.22 per share of common stock and associated warrant exercisable for one share of common stock in a private placement offering by the company made pursuant to Rule 506(c) of the Securities Act of 1933, as amended. The warrants are exercisable immediately, at an exercise price of $1.22 per share, subject to certain adjustments, and expire on January 30, 2029.

SEC source: 0001493152-24-004372 · ownership.xml · derivative · entry 2

Agah Ramtin · CIK 0001862617 · Director · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,983

Underlying: Common Stock · 40,983 shares

Expires not disclosed

F1 · price: Reporting Person purchased 40,983 shares of common stock and warrants to purchase 40,983 shares of common stock for a purchase price of $1.22 per share of common stock and associated warrant exercisable for one share of common stock in a private placement offering by the company made pursuant to Rule 506(c) of the Securities Act of 1933, as amended. These warrants are exercisable immediately, at an exercise price of $1.22 per share, subject to certain adjustments, and expire on January 30, 2029.

F1 · derivative.exercise_date: Reporting Person purchased 40,983 shares of common stock and warrants to purchase 40,983 shares of common stock for a purchase price of $1.22 per share of common stock and associated warrant exercisable for one share of common stock in a private placement offering by the company made pursuant to Rule 506(c) of the Securities Act of 1933, as amended. These warrants are exercisable immediately, at an exercise price of $1.22 per share, subject to certain adjustments, and expire on January 30, 2029.

F1 · derivative.expiration_date: Reporting Person purchased 40,983 shares of common stock and warrants to purchase 40,983 shares of common stock for a purchase price of $1.22 per share of common stock and associated warrant exercisable for one share of common stock in a private placement offering by the company made pursuant to Rule 506(c) of the Securities Act of 1933, as amended. These warrants are exercisable immediately, at an exercise price of $1.22 per share, subject to certain adjustments, and expire on January 30, 2029.

SEC source: 0001493152-24-004372 · ownership.xml · nonDerivative · entry 1

Agah Ramtin · CIK 0001862617 · Director · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 47,460

F1 · price: Reporting Person purchased 40,983 shares of common stock and warrants to purchase 40,983 shares of common stock for a purchase price of $1.22 per share of common stock and associated warrant exercisable for one share of common stock in a private placement offering by the company made pursuant to Rule 506(c) of the Securities Act of 1933, as amended. These warrants are exercisable immediately, at an exercise price of $1.22 per share, subject to certain adjustments, and expire on January 30, 2029.

SEC source: 0001493152-24-004370 · ownership.xml · derivative · entry 2

Spiegel Robert J. · CIK 0001492256 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,983

Underlying: Common Stock · 40,983 shares

Expires not disclosed

F1 · price: Reporting Person purchased 40,983 shares of common stock and warrants to purchase 40,983 shares of common stock for a purchase price of $1.22 per share of common stock and associated warrant exercisable for one share of common stock in a private placement offering by the company made pursuant to Rule 506(c) of the Securities Act of 1933, as amended. The warrants are exercisable immediately, at an exercise price of $1.22 per share, subject to certain adjustments, and expire on January 30, 2029.

F1 · derivative.exercise_date: Reporting Person purchased 40,983 shares of common stock and warrants to purchase 40,983 shares of common stock for a purchase price of $1.22 per share of common stock and associated warrant exercisable for one share of common stock in a private placement offering by the company made pursuant to Rule 506(c) of the Securities Act of 1933, as amended. The warrants are exercisable immediately, at an exercise price of $1.22 per share, subject to certain adjustments, and expire on January 30, 2029.

F1 · derivative.expiration_date: Reporting Person purchased 40,983 shares of common stock and warrants to purchase 40,983 shares of common stock for a purchase price of $1.22 per share of common stock and associated warrant exercisable for one share of common stock in a private placement offering by the company made pursuant to Rule 506(c) of the Securities Act of 1933, as amended. The warrants are exercisable immediately, at an exercise price of $1.22 per share, subject to certain adjustments, and expire on January 30, 2029.

SEC source: 0001493152-24-004370 · ownership.xml · nonDerivative · entry 1

Spiegel Robert J. · CIK 0001492256 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,983

F1 · price: Reporting Person purchased 40,983 shares of common stock and warrants to purchase 40,983 shares of common stock for a purchase price of $1.22 per share of common stock and associated warrant exercisable for one share of common stock in a private placement offering by the company made pursuant to Rule 506(c) of the Securities Act of 1933, as amended. The warrants are exercisable immediately, at an exercise price of $1.22 per share, subject to certain adjustments, and expire on January 30, 2029.

SEC source: 0001493152-24-003521 · ownership.xml · derivative · entry 2

Bagai Shaun · CIK 0001862613 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 250,263

Underlying: Common Stock · 250,263 shares

Expires not disclosed

F2 · derivative.exercise_date: On January 19, 2024, the Reporting Person received a nonqualified stock option grant for a total of 250,263 shares of common stock vesting over four years at a rate of 1/48 per month with no cliff, beginning vesting on February 1, 2024. The option will become fully vested and exercisable on February 1, 2028, and expires on January 19, 2034.

F2 · derivative.expiration_date: On January 19, 2024, the Reporting Person received a nonqualified stock option grant for a total of 250,263 shares of common stock vesting over four years at a rate of 1/48 per month with no cliff, beginning vesting on February 1, 2024. The option will become fully vested and exercisable on February 1, 2028, and expires on January 19, 2034.

SEC source: 0001493152-24-003521 · ownership.xml · derivative · entry 1

Bagai Shaun · CIK 0001862613 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 66,973

Underlying: Common Stock · 66,973 shares

Expires not disclosed

F1 · derivative.exercise_date: On January 19, 2024, the Reporting Person was awarded a stock bonus of 66,973 shares of common stock pursuant to the Company's 2021 Omnibus Equity Incentive Plan (the "Plan"). These shares were fully vested upon issuance to the Reporting Person, expires on January 19, 2034.

F1 · derivative.expiration_date: On January 19, 2024, the Reporting Person was awarded a stock bonus of 66,973 shares of common stock pursuant to the Company's 2021 Omnibus Equity Incentive Plan (the "Plan"). These shares were fully vested upon issuance to the Reporting Person, expires on January 19, 2034.

SEC source: 0001493152-24-003520 · ownership.xml · derivative · entry 2

Agah Ramtin · CIK 0001862617 · Director · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 125,132

Underlying: Common Stock · 125,132 shares

Expires not disclosed

F2 · derivative.exercise_date: On January 19, 2024, the Reporting Person received a nonqualified stock option grant for 125,132 shares of common stock vesting over four years at a rate of 1/48 per month with no cliff, beginning vesting on February 1, 2024. The option will become fully vested and exercisable on February 1, 2028, and expires on January 19, 2034.

F2 · derivative.expiration_date: On January 19, 2024, the Reporting Person received a nonqualified stock option grant for 125,132 shares of common stock vesting over four years at a rate of 1/48 per month with no cliff, beginning vesting on February 1, 2024. The option will become fully vested and exercisable on February 1, 2028, and expires on January 19, 2034.

SEC source: 0001493152-24-003520 · ownership.xml · derivative · entry 1

Agah Ramtin · CIK 0001862617 · Director · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,424

Underlying: Common Stock · 28,424 shares

Expires not disclosed

F1 · derivative.exercise_date: On January 19, 2024, the Reporting Person was awarded a stock bonus of 28,424 shares of common stock pursuant to the Company's 2021 Omnibus Equity Incentive Plan (the "Plan"). These shares were fully vested upon issuance to the Reporting Person, and expire on January 19, 2034.

F1 · derivative.expiration_date: On January 19, 2024, the Reporting Person was awarded a stock bonus of 28,424 shares of common stock pursuant to the Company's 2021 Omnibus Equity Incentive Plan (the "Plan"). These shares were fully vested upon issuance to the Reporting Person, and expire on January 19, 2034.

SEC source: 0001493152-24-003519 · ownership.xml · derivative · entry 2

Nelms Angela · CIK 0001946374 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 125,132

Underlying: Common Stock · 125,132 shares

Expires not disclosed

F2 · derivative.exercise_date: On January 19, 2024, the Reporting Person received a nonqualified stock option grant for a total of 125,132 shares of common stock vesting over four years at a rate of 1/48 per month with no cliff, beginning vesting on February 1, 2024. The option will become fully vested and exercisable on February 1, 2028, and expires on January, 19, 2034.

F2 · derivative.expiration_date: On January 19, 2024, the Reporting Person received a nonqualified stock option grant for a total of 125,132 shares of common stock vesting over four years at a rate of 1/48 per month with no cliff, beginning vesting on February 1, 2024. The option will become fully vested and exercisable on February 1, 2028, and expires on January, 19, 2034.

SEC source: 0001493152-24-003519 · ownership.xml · derivative · entry 1

Nelms Angela · CIK 0001946374 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,768

Underlying: Common Stock · 33,768 shares

Expires not disclosed

F1 · derivative.exercise_date: On January 19, 2024, the Reporting Person was awarded a stock bonus of 33,768 shares of common stock pursuant to the Company's 2021 Omnibus Equity Incentive Plan (the "Plan"). These shares were fully vested upon issuance to the Reporting Person, and expire on January 19, 2034.

F1 · derivative.expiration_date: On January 19, 2024, the Reporting Person was awarded a stock bonus of 33,768 shares of common stock pursuant to the Company's 2021 Omnibus Equity Incentive Plan (the "Plan"). These shares were fully vested upon issuance to the Reporting Person, and expire on January 19, 2034.

SEC source: 0001493152-23-035684 · ownership.xml · nonDerivative · entry 2

Nelms Angela · CIK 0001946374 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,100

SEC source: 0001493152-23-035684 · ownership.xml · nonDerivative · entry 1

Nelms Angela · CIK 0001946374 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 300

SEC source: 0001493152-23-035034 · ownership.xml · derivative · entry 1

Macfarlane K. Angela · CIK 0001865182 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,099

Underlying: Common Stock · 25,099 shares

Expires 2033-10-01

F1 · derivative.exercise_date: The shares subject to the option vest in 12 equal monthly installments beginning on November 1, 2023

SEC source: 0001493152-23-035035 · ownership.xml · derivative · entry 1

Marton Laurence · CIK 0001862192 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,099

Underlying: Common Stock · 25,099 shares

Expires 2033-10-01

F1 · derivative.exercise_date: The shares subject to the option vest in 12 equal monthly installments beginning on November 1, 2023

SEC source: 0001493152-23-035033 · ownership.xml · derivative · entry 1

Diamond David · CIK 0001802807 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,099

Underlying: Common Stock · 25,099 shares

Expires 2033-10-01

F1 · derivative.exercise_date: The shares subject to the option vest in 12 equal monthly installments beginning on November 1, 2023

SEC source: 0001493152-23-035037 · ownership.xml · derivative · entry 1

Spiegel Robert J. · CIK 0001492256 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,099

Underlying: Common Stock · 25,099 shares

Expires 2033-10-01

F1 · derivative.exercise_date: The shares subject to the option vest in 12 equal monthly installments beginning on November 1, 2023

SEC source: 0001493152-23-035036 · ownership.xml · derivative · entry 1

RYAN UNA S · CIK 0001255349 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,099

Underlying: Common Stock · 25,099 shares

Expires 2033-10-01

F1 · derivative.exercise_date: The shares subject to the option vest in 12 equal monthly installments beginning on November 1, 2023

SEC source: 0001493152-23-013843 · ownership.xml · derivative · entry 1

Spiegel Robert J. · CIK 0001492256 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 43,026

Underlying: Common Stock · 43,026 shares

Expires 2033-04-25

F1 · derivative.exercise_date: Shares subject to the option vest in 36 monthly installments beginning on May 25, 2023.

SEC source: 0001493152-23-009494 · ownership.xml · derivative · entry 1

Bagai Shaun · CIK 0001862613 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 130,000

Underlying: Common Stock · 130,000 shares

Expires 2033-03-15

F1 · derivative.exercise_date: The shares subject to the option vest in 48 equal monthly installments beginning on January 1, 2023.

SEC source: 0001493152-23-009504 · ownership.xml · derivative · entry 1

Agah Ramtin · CIK 0001862617 · Director · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,000

Underlying: Common Stock · 65,000 shares

Expires 2033-03-15

F1 · derivative.exercise_date: The shares subject to the option vest in 48 equal monthly installments beginning on January 1, 2023.

SEC source: 0001493152-23-009489 · ownership.xml · derivative · entry 1

Nelms Angela · CIK 0001946374 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,500

Underlying: Common Stock · 32,500 shares

Expires 2033-03-15

F1 · derivative.exercise_date: The shares subject to the option vest in 48 equal monthly installments beginning on January 1, 2023.

SEC source: 0001209191-22-055815 · doc4.xml · derivative · entry 2

Marton Laurence · CIK 0001862192 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 25,438 shares

Expires 2023-04-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: Shares subject to the option are fully vested and immediately exercisable.

SEC source: 0001209191-22-055815 · doc4.xml · nonDerivative · entry 1

Marton Laurence · CIK 0001862192 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,438

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-22-052244 · doc4.xml · derivative · entry 1

Macfarlane K. Angela · CIK 0001865182 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,099

Underlying: Common Stock · 25,099 shares

Expires 2032-10-01

F1 · derivative.exercise_date: The shares subject to the option vest in 12 equal monthly installments beginning on November 1, 2022.

SEC source: 0001209191-22-052262 · doc4.xml · derivative · entry 1

Marton Laurence · CIK 0001862192 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,099

Underlying: Common Stock · 25,099 shares

Expires 2032-10-01

F1 · derivative.exercise_date: The shares subject to the option vest in 12 equal monthly installments beginning on November 1, 2022.

SEC source: 0001209191-22-052234 · doc4.xml · derivative · entry 1

Diamond David · CIK 0001802807 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,099

Underlying: Common Stock · 25,099 shares

Expires 2032-10-01

F1 · derivative.exercise_date: The shares subject to the option vest in 12 equal monthly installments beginning on November 1, 2022.

SEC source: 0001209191-22-052309 · doc4.xml · derivative · entry 1

RYAN UNA S · CIK 0001255349 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,099

Underlying: Common Stock · 25,099 shares

Expires 2032-10-01

F1 · derivative.exercise_date: The shares subject to the option vest in 12 equal monthly installments beginning on November 1, 2022.

SEC source: 0001209191-22-050898 · doc4.xml · derivative · entry 1

Nelms Angela · CIK 0001946374 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 274,230

Underlying: Common Stock · 274,230 shares

Expires 2032-09-19

F1 · derivative.exercise_date: One-fourth of the shares subject to the option vest on September 19, 2023 and 1/36th of the remaining shares vest monthly thereafter.

SEC source: 0001493152-22-016226 · ownership.xml · nonDerivative · entry 3

Agah Ramtin · CIK 0001862617 · Director · Chief Medical Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,477

SEC source: 0001209191-22-031236 · doc4.xml · nonDerivative · entry 1

Bagai Shaun · CIK 0001862613 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 251,557

F1 · balance_after: Includes 246,057 shares previously reported on a Form 3 filed on August 25, 2021 as a fully vested stock option exercisable at $0.15 per share. The option was exercised in full prior to the Issuer's initial public offering.

SEC source: 0001493152-26-029958 · ownership.xml · nonDerivative · entry 4

RYAN UNA S · CIK 0001255349 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · The Una S. Ryan Revocable Trust

Disclosed balance after: 97,165

F2 · kind: Reflects distribution from Golden Seeds Venture Fund GP, of which the reporting person is a non-managing member.

SEC source: 0001493152-26-029958 · ownership.xml · nonDerivative · entry 3

RYAN UNA S · CIK 0001255349 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · The Una S. Ryan Revocable Trust

Disclosed balance after: 80,959

F2 · kind: Reflects distribution from Golden Seeds Venture Fund GP, of which the reporting person is a non-managing member.

SEC source: 0001493152-22-016226 · ownership.xml · nonDerivative · entry 2

Agah Ramtin · CIK 0001862617 · Director · Chief Medical Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 975,000

F1 · ownership.nature: The shares are held of record by the Mars16 Nevada Non-Grantor Trust Dtd 01/19/2016.